| Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation H Zhang, D Freitas, HS Kim, K Fabijanic, Z Li, H Chen, MT Mark, H Molina, ... Nature cell biology 20 (3), 332-343, 2018 | 1351 | 2018 |
| Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization P Giannakakou, DL Sackett, YK Kang, Z Zhan, JTM Buters, T Fojo, ... Journal of Biological Chemistry 272 (27), 17118-17125, 1997 | 917 | 1997 |
| 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF NJ Mabjeesh, D Escuin, TM LaVallee, VS Pribluda, GM Swartz, ... Cancer cell 3 (4), 363-375, 2003 | 915 | 2003 |
| Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol®) RJ Kowalski, P Giannakakou, E Hamel Journal of Biological Chemistry 272 (4), 2534-2541, 1997 | 718 | 1997 |
| Synthesis of epothilones A and B in solid and solution phase KC Nicolaou, N Winssinger, J Pastor, S Ninkovic, F Sarabia, Y He, ... Nature 387 (6630), 268-272, 1997 | 632 | 1997 |
| A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells P Giannakakou, R Gussio, E Nogales, KH Downing, D Zaharevitz, ... Proceedings of the National Academy of Sciences 97 (6), 2904-2909, 2000 | 626 | 2000 |
| Targeting microtubules for cancer chemotherapy J Zhou, P Giannakakou Current Medicinal Chemistry-Anti-Cancer Agents 5 (1), 65-71, 2005 | 618 | 2005 |
| Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death MV Blagosklonny, P Giannakakou, WS El-Deiry, DGI Kingston, PI Higgs, ... Cancer research 57 (1), 130-135, 1997 | 522 | 1997 |
| Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways TH Wang, HS Wang, H Ichijo, P Giannakakou, JS Foster, T Fojo, ... Journal of Biological Chemistry 273 (9), 4928-4936, 1998 | 507 | 1998 |
| Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer MS Darshan, MS Loftus, M Thadani-Mulero, BP Levy, D Escuin, XK Zhou, ... Cancer research 71 (18), 6019-6029, 2011 | 482 | 2011 |
| Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody JP Gleghorn, ED Pratt, D Denning, H Liu, NH Bander, ST Tagawa, ... Lab on a Chip 10 (1), 27-29, 2010 | 469 | 2010 |
| p53 is associated with cellular microtubules and is transported to the nucleus by dynein P Giannakakou, DL Sackett, Y Ward, KR Webster, MV Blagosklonny, ... Nature cell biology 2 (10), 709-717, 2000 | 462 | 2000 |
| The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more … RJ Kowalski, P Giannakakou, SP Gunasekera, RE Longley, BW Day, ... Molecular pharmacology 52 (4), 613-622, 1997 | 343 | 1997 |
| The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for … DE Pryor, A O'Brate, G Bilcer, JF Díaz, Y Wang, Y Wang, M Kabaki, ... Biochemistry 41 (29), 9109-9115, 2002 | 312 | 2002 |
| Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study AJ Armstrong, S Halabi, J Luo, DM Nanus, P Giannakakou, ... Journal of Clinical Oncology 37 (13), 1120, 2019 | 307 | 2019 |
| Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity P Giannakakou, R Robey, T Fojo, MV Blagosklonny Oncogene 20 (29), 3806-3813, 2001 | 304 | 2001 |
| The importance of p53 location: nuclear or cytoplasmic zip code? A O’Brate, P Giannakakou Drug resistance updates 6 (6), 313-322, 2003 | 297 | 2003 |
| Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device BJ Kirby, M Jodari, MS Loftus, G Gakhar, ED Pratt, C Chanel-Vos, ... PloS one 7 (4), e35976, 2012 | 292 | 2012 |
| Androgen receptor splice variants determine taxane sensitivity in prostate cancer M Thadani-Mulero, L Portella, S Sun, M Sung, A Matov, RL Vessella, ... Cancer research 74 (8), 2270-2282, 2014 | 267 | 2014 |
| A SIRT2-selective inhibitor promotes c-Myc oncoprotein degradation and exhibits broad anticancer activity H Jing, J Hu, B He, YLN Abril, J Stupinski, K Weiser, M Carbonaro, ... Cancer cell 29 (3), 297-310, 2016 | 262 | 2016 |
